Pharming Group Competitors and Similar CompaniesClear all
Pharming Group's competitors and similar companies include Protalix BioTherapeutics, Five Prime Therapeutics, Ambrx and Strategic Partners.
 Pharming Group Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases. |  Protalix BioTherapeutics Protalix is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins. |  Five Prime Therapeutics Five Prime Therapeutics is a biotechnology company focused on developing immuno-oncology and targeted cancer therapies. |  Ambrx Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code. |  Strategic Partners Strategic Partners (formerly known as Orphazyme) is a company that forms partnerships with biotech, industrial, commercial, property, and asset management companies. | |
Founding Date | Founding Date 1988 | Founding Date 1994 | Founding Date 2001 | Founding Date 2003 | Founding Date 2009 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Public |
Tags | |||||
Locations | Locations Leiden, NL HQ Leiden, NL | Locations Karmiel, IL HQ | Locations South San Francisco, US HQ | Locations San Diego, US HQ | Locations København, DK HQ Chicago, US Newton, US |
Employees | Employees 404 | Employees 213 | Employees 5141% decrease | Employees 70 | Employees 1 |
Valuation ($) | Valuation ($) 590.3 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1.8 b | Valuation ($) 6.8 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $376.1m (FY, 2025) | Revenue (est.) $52.7m (FY, 2025) | Revenue (est.) $13.2m (FY, 2020) | Revenue (est.) $7.4m (FY, 2022) | Revenue (est.) kr309k (FY, 2025) |
Cost of goods | Cost of goods $41.6m (FY, 2025) | Cost of goods $25.5m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $341m (FY, 2025) | Gross profit $27.2m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit kr309k (FY, 2025) |
Net income | Net income $2.5m (FY, 2025) | Net income ($6.6m) (FY, 2025) | Net income ($84.3m) (FY, 2020) | Net income ($78m) (FY, 2022) | Net income (kr859k) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 62.5m | Total funding raised $ 237.2m | Total funding raised $ 347.9m | Total funding raised $ 58.8m |
For sources of this data, please see the company profile
View Company Profiles
Protalix BioTherapeutics
HQ
Karmiel, IL
Employees
213
Protalix is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins.
View companyFive Prime Therapeutics
HQ
South San Francisco, US
Five Prime Therapeutics is a biotechnology company focused on developing immuno-oncology and targeted cancer therapies.
View companyAmbrx
HQ
San Diego, US
Employees
70
Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code.
View companyStrategic Partners
HQ
København, DK
Employees
1
Strategic Partners (formerly known as Orphazyme) is a company that forms partnerships with biotech, industrial, commercial, property, and asset management companies.
View company